Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53

Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53

Background/Aims: Rapamycin is a potential anti-cancer agent, which modulates the activity of mTOR, a key regulator of cell growth and proliferation. However, several types of cancer cells are resistant to the anti-proliferative effects of rapamycin. In this study, we report a MDM2/p53-mediated rapam...

Full description

Bibliographic Details
Main Authors: Xin Tian, Shundong Dai, Jing Sun, Shenyi Jiang, Chengguang Sui, Fandong Meng, Yan Li, Liye Fu, Tao Jiang, Yang Wang, Jia Su, Youhong Jiang
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2016-10-01
Series:Cellular Physiology and Biochemistry
Subjects:
MDM2
p53
Rapamycin
Renal cancer
Online Access:http://www.karger.com/Article/FullText/447904

Similar Items

Similar Items